Mayes College of Healthcare Business and Policy presents
Making the Connections: The New 4Ps of CER: Pharma, Payer, Provider, and Patient.
Comparative Effectiveness Research (CER) is just a single step in a series of advances in medicine seeking to better understand “value” at the patient level. After more than three decades of double digit growth in healthcare spending, CER is the next logical step, and likely not the last. The aging population, increase in covered lives, and most notably a vast array of advances in healthcare technology, have inevitably lead us to the point of needing a far more practical and “real world” understanding of how different treatment choices can impact patient level outcomes.
This panel discussion, featuring a panel of renowned speakers, will offer a novel look into the perspectives of the major stakeholders in CER—The pharmaceutical industry, the payer, the healthcare provider and the patient.
Tuesday, April 16, 2013, from 5:30 to 8:30 p.m.
Reception to follow
University of the Sciences
McNeil Science and Technology Center
AstraZeneca Auditorium
45th Street at Woodland Avenue
Philadelphia, Pa. 19104
RSVP requested. Click here to register online.
For more information, e-mail MayesCollegeConnections@usciences.edu or call 866.431.0845.
Made possible by an unrestricted educational grant from AstraZeneca Pharmaceuticals.
Speakers
Michael W. Painter, JD, MD
Senior Program Officer
Robert Wood Johnson Foundation
Dr. Painter is a physician, attorney, healthcare policy advocate who serves as a member of the RWJF Pioneer Portfolio and Quality/Equality teams. In 2003-04, Dr. Painter was a RWJF Health Policy Fellow with the office of Senator William H. Frist, MD, a former majority leader. Prior to that, he was the chief of medical staff at the Seattle Indian Health Board, a community health center serving urban American Indians and Alaska Natives. Dr. Painter led that clinic’s award-winning diabetes team. He has a clinical faculty appointment with the University of Washington, Department of Family Medicine, and is a board-certified family physician. He also holds a BA in economics and mathematics from Vanderbilt University.
David Hickam, MD, MPH
Program Director, Assessment of Prevention, Diagnosis, and Treatment Options Program
Patient-Centered Outcomes Research Institute
Dr. Hickam is a specialist in internal medicine and has 30 years of experience as a health services researcher. His past research has focused on strategies for improving healthcare outcomes among adults with chronic diseases. He is responsible for developing PCORI’s research program that evaluates comparisons among alternative clinical strategies in a broad range of clinical domains. Dr. Hickam who was a professor in the Department of Medicine at Oregon Health and Science University, became the founding Director of the John M. Eisenberg Clinical Decisions and Communications Science Center in 2005.
Brian Sweet, RPh, MBA
Executive Director, Healthcare Alliances
AstraZeneca Pharmaceuticals, LP
Mr. Sweet is focused on AstraZeneca’s initiatives in real world evidence and comparative effectiveness research and collaborating with health plans, pharmacy benefit managers, and a variety of key business partners. In addition, he coordinates with managed markets customers on the development of performance-driven models, health improvement programs, value-based insurance designs, and evolving healthcare reform issues. Mr. Sweet is the former chief pharmacy officer of WellPoint, Inc., located in Indianapolis. There he was responsible for overseeing all clinical pharmacy services, including leading the national pharmacy and therapeutics committee, which uses integrated data analyses and total cost of care modeling to improve patient health outcomes.
I. Steven Udvarhelyi, MD
Executive Vice President, Health Services, and Chief Strategy Officer
Independence Blue Cross
In his role as Executive Vice President, Health Services at IBC, Dr. Udvarhelyi has responsibility for clinical services, provider contracting and provider relations, and informatics. In addition, as Chief Strategy Officer, he is responsible for working with the senior leadership to oversee both the development and execution of corporate and functional strategies for IBC to achieve its vision and mission. Dr. Udvarhelyi is a board certified internist and has more than 20 years of experience in the managed care industry. Prior to his career in the managed care and insurance industry, Dr. Udvarhelyi was a faculty member at Harvard Medical School and has published numerous articles on quality in health care.
Moderator
Jean-Paul Gagnon, PhD
Senior Director, US Policy and Strategic Advocacy
Sanofi (retired)
Dr. Gagnon was employed by Sanofi for 22 years and was given the company's Pinnacle Award in recognition of his work on a Biological Properties Initiative. In his past position at Sanofi, he was responsible for its US involvement with various governmental policy issues including comparative effectiveness and health information technology. He continues to follow these and other evolving health policy issues. He was a Robert Wood Johnson Health Policy Fellow in Washington, D.C. And among his activities and honors, he was a past president of the American Association of Colleges of Pharmacy and received the APhA Foundation/Academy of Pharmaceutical Sciences Research Achievement Award in Economic, Social, and Administrative Sciences.
Continuing Education
Making the Connections - The New 4Ps of CER - Pharma, Payer, Provider, & Patient is a knowledge-based, CPE activity. In order to obtain credit attendees must participate in the entire program and complete the online evaluation and learning assessment with a score of 70% or higher.
Objectives:
- Describe the similarities and differences of the various definitions of Comparative Effectiveness Research (CER)
- Explain how the pharmaceutical industry and payers will use or respond to CER data in their respective industries
- Describe three ways CER will impact clinical practice in the future by the time PCORI is evaluated by the GAO
- Explain the role of the “patient” in CER and especially in reference to PCORI funded research opportunities
The Philadelphia College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program (0056-9999-13-101-L04-P) is acceptable for 2 contact hours of continuing education credit in states that recognize ACPE approved providers. In order to receive credit, you must complete the online evaluation and learning assessment with a score of 70% or higher.
About Mayes
Mayes College of Healthcare Business and Policy
Healthcare and pharmaceutical spending is more than 1/6 of the US economy. Mayes College of Healthcare Business and Policy, located in the center of the Northeast pharmaceutical corridor, educates the people who keep the healthcare industry moving. Business leaders, policy makers, researchers, and healthcare writers learn how to have a positive impact on the business of healthcare at Mayes.
Mayes provides education in specialized fields like Biomedical Writing, Pharmaceutical and Healthcare Business, Health Policy and Public Health, and provides students with hands-on learning experiences, internships, and personal connections. This gives our graduates a leg up on the competition when it comes to career prospects in healthcare industries.
